Relationship of cortisol levels and genetic polymorphisms to antidepressant response to placebo and fluoxetine in patients with major depressive disorder: a prospective study

BMC Psychiatry

Luisa Herrera⁵  Jaime Sasso⁴  A Verónica Araya³  Viviana Guajardo⁶  Felipe Marín⁶  Pamela Lara⁶  Cristóbal Heskia⁵  Graciela Rojas⁶  Jenny L Fiedler¹  Pamela López⁵  Adriana Symon⁵  Raúl Ventura-Juncá² 

[1] Laboratorio de Neuroplasticidad y Neurogenética, Departamento de Bioquímica y Biología Molecular, Universidad de Chile, Calle Sergio Livingstone Pohlhammer 1007 (ex Olivos), Independencia, Santiago, Chile;Escuela de Psicología, Universidad de Los Andes, San Carlos de Apoquindo 2200, Las Condes, Santiago, Chile;Departamento de Endocrinología, Universidad de Chile, Santos Dumont 999, Independencia, Santiago, Chile;Instituto de Investigaciones Farmacológicas y Toxicológicas (IFT), Facultad de Medicina, Universidad de Chile, Santiago, Chile;Programa de Genética Humana, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Independencia 1027, Independencia, Santiago, Chile;Clínica Psiquiátrica Universitaria, Hospital Clínico Universidad de Chile, Av. La Paz 1003, Recoleta, Santiago, Chile

关键词: Polymorphisms;    Antidepressants;    Fluoxetine;    Placebo;    Salivary cortisol;    Major depressive disorder;   

Others  :  1123426
DOI  :  10.1186/s12888-014-0220-0

 received in 2014-04-28, accepted in 2014-07-23,  发布年份 2014

【 摘 要 】

Background

Increased cortisol levels and genetic polymorphisms have been related to both major depressive disorder and antidepressant treatment outcome. The aim of this study is to evaluate the relationship between circadian salivary cortisol levels, cortisol suppression by dexamethasone and genetic polymorphisms in some HPA axis-related genes to the response to placebo and fluoxetine in depressed patients.

Methods

The diagnosis and severity of depression were performed using the Mini International Neuropsychiatric Interview (M.I.N.I.) and Hamilton depression scale (HAM-D₁₇), respectively. Euthyroid patients were treated with placebo (one week) followed by fluoxetine (20 mg) (two months). Severity of depression was re-evaluated after placebo, three weeks and two months of fluoxetine treatments. Placebo response was defined as HAM-D₁₇ score reductions of at least 25% and to < 15. Early response and response were reductions of at least 50% after three weeks and two months, and remission with ≤ 7 after two months. Plasma TSH, free-T4, circadian salivary cortisol levels and cortisol suppression by dexamethasone were evaluated. Seven genetic polymorphisms located in the Corticotrophin-releasing-hormone-receptor-1 (rs242939, rs242941, rs1876828), Corticotrophin-releasing-hormone-receptor-2 (rs2270007), Glucocorticoid-receptor (rs41423247), FK506-binding-protein-5 (rs1360780), and Arginine-vasopressin (rs3729965) genes were determined. Association analyses between response to placebo/fluoxetine and polymorphism were performed by chi-square or Fisher exact test. Cortisol levels were compared by t-test, ANOVA and the general linear model for repeated measures.

Results

208 depressed patients were recruited, 187 of whom were euthyroid. Placebo responders, fluoxetine responders and remitters exhibited significantly lower circadian cortisol levels than those who did not respond (p-values of 0.014, 0.008 and 0.021 respectively). Patients who abandoned treatment before the third week also exhibited a trend to low cortisol levels (p = 0.057). The polymorphisms rs242939 (CRHR1) and rs2270007 (CRHR2) were not in Hardy-Weinberg equilibrium. Only the rs242939 polymorphism (CRHR1) exhibited association with early response (three weeks) to fluoxetine (p-value = 0.043). No other association between outcomes and polymorphisms was observed.

Conclusions

These results support the clinical relevance of low salivary cortisol levels as a predictor of antidepressant response, either to placebo or to fluoxetine. Only one polymorphism in the CRHR1 gene was associated with the early response. Other factors may be involved in antidepressant response, although further studies are needed to identify them.

【 授权许可】

   
2014 Ventura-Juncá et al., licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Vicente B, Kohn R, Rioseco P, Saldivia S, Levav I, Torres S: Lifetime and 12-month prevalence of DSM-III-R disorders in the Chile psychiatric prevalence study. Am J Psychiatry 2006, 163(8):1362-1370.
• [2]Kendler KS, Thornton LM, Gardner CO: Stressful life events and previous episodes in the etiology of major depression in women: an evaluation of the “kindling” hypothesis. Am J Psychiatry 2000, 157(8):1243-1251.
• [3]Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC: Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 2007, 62(11):1217-1227.
• [4]Gartlehner G, Chapman A, Strobelberger M, Thaler K: Differences in efficacy and safety of pharmaceutical treatments between men and women: an umbrella review. PLoS One 2010, 5(7):e11895.
• [5]Anacker C, Zunszain PA, Carvalho LA, Pariante CM: The glucocorticoid receptor: pivot of depression and of antidepressant treatment? Psychoneuroendocrinology 2011, 36(3):415-425.
• [6]Horstmann S, Binder EB: Glucocorticoids as predictors of treatment response in depression. Harv Rev Psychiatry 2011, 19(3):125-143.
• [7]Wong ML, Licinio J: Research and treatment approaches to depression. Nat Rev Neurosci 2001, 2(5):343-351.
• [8]Fernández-Guasti AF, Herrera L, Handa R: Sex, stress and mood disorders: at the intersection of adrenal and gonadal hormones. Horm Metab Res 2012, 44(8):607-618.
• [9]Varghese FP, Brown ES: The hypothalamic-pituitary-adrenal axis in major depressive disorder: a brief primer for primary care physicians. Prim Care Companion J Clin Psychiatry 2001, 3(4):151-155.
• [10]Ribeiro SC, Tandon R, Grunhaus L, Greden JF: The DST as a predictor of outcome in depression: a meta-analysis. Am J Psychiatry 1993, 150(11):1618-1629.
• [11]Kirsch I: Challenging received wisdom: antidepressants and the placebo effect. McGill J Med 2008, 11(2):219-222.
• [12]Mayberg HS, Silva JA, Brannan SK, Tekell JL, Mahurin RK, McGinnis S, Jerabek PA: The functional neuroanatomy of the placebo effect. Am J Psychiatry 2002, 159(5):728-737.
• [13]Vallance AK: A systematic review comparing the functional neuroanatomy of patients with depression who respond to placebo to those who recover spontaneously: is there a biological basis for the placebo effect in depression? J Affect Disord 2007, 98(1–2):177-185.
• [14]Baes C, Martins CM, Tofoli SM, Juruena MF: Early life stress in depressive patients: HPA axis response to GR and MR Agonist. Front Psychiatry 2014, 5:2.
• [15]Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Putz B, Papiol S, Seaman S, Lucae S, Kohli MA, Nickel T, Kunzel HE, Fuchs B, Majer M, Pfennig A, Kern N, Brunner J, Modell S, Baghai T, Deiml T, Zill P, Bondy B, Rupprecht R, Messer T, Kohnlein O, Dabitz H, Bruckl T, Muller N, Pfister H, Lieb R, et al.: Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 2004, 36(12):1319-1325.
• [16]Liu Z, Zhu F, Wang G, Xiao Z, Tang J, Liu W, Wang H, Liu H, Wang X, Wu Y, Cao Z, Li W: Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. Neurosci Lett 2007, 414(2):155-158.
• [17]Papiol S, Arias B, Gasto C, Gutierrez B, Catalan R, Fananas L: Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J Affect Disord 2007, 104(1–3):83-90.
• [18]Brouwer JP, Appelhof BC, van Rossum EF, Koper JW, Fliers E, Huyser J, Schene AH, Tijssen JG, Van Dyck R, Lamberts SW, Wiersinga WM, Hoogendijk WJ: Prediction of treatment response by HPA-axis and glucocorticoid receptor polymorphisms in major depression. Psychoneuroendocrinology 2006, 31(10):1154-1163.
• [19]van Rossum EF, Binder EB, Majer M, Koper JW, Ising M, Modell S, Salyakina D, Lamberts SW, Holsboer F: Polymorphisms of the glucocorticoid receptor gene and major depression. Biol Psychiatry 2006, 59(8):681-688.
• [20]Galecka E, Szemraj J, Bienkiewicz M, Majsterek I, Przybylowska-Sygut K, Galecki P, Lewinski A: Single nucleotide polymorphisms of NR3C1 gene and recurrent depressive disorder in population of Poland. Mol Biol Rep 2013, 40(2):1693-1699.
• [21]Liu Z, Zhu F, Wang G, Xiao Z, Wang H, Tang J, Wang X, Qiu D, Liu W, Cao Z, Li W: Association of corticotropin-releasing hormone receptor1 gene SNP and haplotype with major depression. Neurosci Lett 2006, 404(3):358-362.
• [22]Licinio J, O’Kirwan F, Irizarry K, Merriman B, Thakur S, Jepson R, Lake S, Tantisira KG, Weiss ST, Wong ML: Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Mol Psychiatry 2004, 9(12):1075-1082.
• [23]Bale TL, Contarino A, Smith GW, Chan R, Gold LH, Sawchenko PE, Koob GF, Vale WW, Lee KF: Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet 2000, 24(4):410-414.
• [24]Coste SC, Kesterson RA, Heldwein KA, Stevens SL, Heard AD, Hollis JH, Murray SE, Hill JK, Pantely GA, Hohimer AR, Hatton DC, Phillips TJ, Finn DA, Low MJ, Rittenberg MB, Stenzel P, Stenzel-Poore MP: Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat Genet 2000, 24(4):403-409.
• [25]Wotjak CT, Ludwig M, Ebner K, Russell JA, Singewald N, Landgraf R, Engelmann M: Vasopressin from hypothalamic magnocellular neurons has opposite actions at the adenohypophysis and in the supraoptic nucleus on ACTH secretion. Eur J Neurosci 2002, 16(3):477-485.
• [26]Nakase S, Kitayama I, Soya H, Hamanaka K, Nomura J: Increased expression of magnocellular arginine vasopressin mRNA in paraventricular nucleus of stress-induced depression-model rats. Life Sci 1998, 63(1):23-31.
• [27]Murgatroyd C, Wigger A, Frank E, Singewald N, Bunck M, Holsboer F, Landgraf R, Spengler D: Impaired repression at a vasopressin promoter polymorphism underlies overexpression of vasopressin in a rat model of trait anxiety. J Neurosci 2004, 24(35):7762-7770.
• [28]Landgraf R, Kessler MS, Bunck M, Murgatroyd C, Spengler D, Zimbelmann M, Nussbaumer M, Czibere L, Turck CW, Singewald N, Rujescu D, Frank E: Candidate genes of anxiety-related behavior in HAB/LAB rats and mice: focus on vasopressin and glyoxalase-I. Neurosci Biobehav Rev 2007, 31(1):89-102.
• [29]Altemus M, Cizza G, Gold PW: Chronic fluoxetine treatment reduces hypothalamic vasopressin secretion in vitro. Brain Res 1992, 593(2):311-313.
• [30]Araya R, Wynn R, Lewis G: Comparison of two self administered psychiatric questionnaires (GHQ-12 and SRQ-20) in primary care in Chile. Soc Psychiatry Psychiatr Epidemiol 1992, 27(4):168-173.
• [31]Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR: Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999, 282(15):1458-1465.
• [32]Von Korff M, Shapiro S, Burke JD, Teitlebaum M, Skinner EA, German P, Turner RW, Klein L, Burns B: Anxiety and depression in a primary care clinic. Comparison of diagnostic interview schedule, general health questionnaire, and practitioner assessments. Arch Gen Psychiatry 1987, 44(2):152-156.
• [33]Sheehan DVLY, Harnett-Sheehan K, Amorim P, Janavs J, Weiller EHT, Baker R, Dunbar G: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interviewfor DSMIV and ICD-10. J Clin Psychiatry 1998, 59(Suppl 20):22-33.
• [34]Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
• [35]Stassen HH, Angst J, Hell D, Scharfetter C, Szegedi A: Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. J Clin Psychiatry 2007, 68(8):1195-1205.
• [36]Mosso L, Margozzini P, Trejo P, Dominguez A, Solari S, Valdivia G, Arteaga E: Thyroid stimulating hormone reference values derived from the 2009–2010 Chilean National Health Survey. Rev Med Chil 2013, 141(1):95-103.
• [37]Peralta Watt M, Penalver Talavera D: Panhypopituitarism due to craniopharyngioma associated with hyperthyroidism caused by graves’ disease. Endocrinol Nutr 2008, 55(7):297-300.
• [38]Araya AV, Rojas P, Fritsch R, Rojas R, Herrera L, Rojas G, Gatica H, Silva H, Fiedler JL: Early response to venlafaxine antidepressant correlates with lower ACTH levels prior to pharmacological treatment. Endocrine 2006, 30(3):289-298.
• [39]Stewart PM KN: The Adrenal Cortex. In Williams Textbook of Endocrinology. 12th edition. Edited by Kronenberg HM, Melmed S, Polonsky KS, Larsen PR. Saunders Elsevier, Philadelphia, PA; 2011. chap 15
• [40]Lahiri DK, Nurnberger JI Jr: A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 1991, 19(19):5444.
• [41]Cornfield J: A Statistical Problem Arising From Retrospective Studies., vol. Volume IV, (Negman, J. ed.). University of California Press, Berkeley; 1956.
• [42]Fardella C, Gloger S, Figueroa R, Santis R, Gajardo C, Salgado C, Barroilhet S, Foradori A: High prevalence of thyroid abnormalities in a Chilean psychiatric outpatient population. J Endocrinol Invest 2000, 23(2):102-106.
• [43]Vanderpump MP: The epidemiology of thyroid disease. Br Med Bull 2011, 99:39-51.
• [44]Tavel ME: The placebo effect: the good, the bad and the ugly. Am J Med 2014, 2014:2014.
• [45]Rutherford BR, Roose SP: A model of placebo response in antidepressant clinical trials. Am J Psychiatry 2013, 170(7):723-733.
• [46]Rutherford BR, Sneed JR, Roose SP: Does study design influence outcome? The effects of placebo control and treatment duration in antidepressant trials. Psychother Psychosom 2009, 78(3):172-181.
• [47]Walsh BT, Seidman SN, Sysko R, Gould M: Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002, 287(14):1840-1847.
• [48]Benedetti F, Mayberg HS, Wager TD, Stohler CS, Zubieta JK: Neurobiological mechanisms of the placebo effect. J Neurosci 2005, 25(45):10390-10402.
• [49]Benedetti F, Pollo A, Lopiano L, Lanotte M, Vighetti S, Rainero I: Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. J Neurosci 2003, 23(10):4315-4323.
• [50]Knorr U, Vinberg M, Kessing LV, Wetterslev J: Salivary cortisol in depressed patients versus control persons: a systematic review and meta-analysis. Psychoneuroendocrinology 2010, 35(9):1275-1286.
• [51]Buchanan TW, Lovallo WR: Enhanced memory for emotional material following stress-level cortisol treatment in humans. Psychoneuroendocrinology 2001, 26(3):307-317.
• [52]Oken BS: Placebo effects: clinical aspects and neurobiology. Brain 2008, 131(Pt 11):2812-2823.
• [53]Miller FG, Kaptchuk TJ: The power of context: reconceptualizing the placebo effect. J R Soc Med 2008, 101(5):222-225.
• [54]Mondloch MV, Cole DC, Frank JW: Does how you do depend on how you think you’ll do? A systematic review of the evidence for a relation between patients’ recovery expectations and health outcomes. CMAJ 2001, 165(2):174-179.
• [55]Volkow ND, Wang GJ, Ma Y, Fowler JS, Zhu W, Maynard L, Telang F, Vaska P, Ding YS, Wong C, Swanson JM: Expectation enhances the regional brain metabolic and the reinforcing effects of stimulants in cocaine abusers. J Neurosci 2003, 23(36):11461-11468.
• [56]Kirschbaum C, Hellhammer DH: Salivary cortisol in psychoneuroendocrine research: recent developments and applications. Psychoneuroendocrinology 1994, 19(4):313-333.
• [57]Pariante CM, Miller AH: Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001, 49(5):391-404.
• [58]Villafuerte SM, Del-Favero J, Adolfsson R, Souery D, Massat I, Mendlewicz J, Van Broeckhoven C, Claes S: Gene-based SNP genetic association study of the corticotropin-releasing hormone receptor-2 (CRHR2) in major depression. Am J Med Genet 2002, 114(2):222-226.
• [59]Claes S: Glucocorticoid receptor polymorphisms in major depression. Ann N Y Acad Sci 2009, 1179:216-228.
• [60]Ellsworth KA, Moon I, Eckloff BW, Fridley BL, Jenkins GD, Batzler A, Biernacka JM, Abo R, Brisbin A, Ji Y, Hebbring S, Wieben ED, Mrazek DA, Weinshilboum RM, Wang L: FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder. Pharmacogenet Genomics 2013, 23(3):156-166.
• [61]Binder EB, Owens MJ, Liu W, Deveau TC, Rush AJ, Trivedi MH, Fava M, Bradley B, Ressler KJ, Nemeroff CB: Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. Arch Gen Psychiatry 2010, 67(4):369-379.
• [62]Xiao Z, Liu W, Gao K, Wan Q, Yang C, Wang H, Wang X, Wang G, Liu Z: Interaction between CRHR1 and BDNF genes increases the risk of recurrent major depressive disorder in Chinese population. PLoS One 2011, 6(12):e28733.
• [63]Surget A, Belzung C: Involvement of vasopressin in affective disorders. Eur J Pharmacol 2008, 583(2–3):340-349.
• [64]Van Pett K, Viau V, Bittencourt JC, Chan RK, Li HY, Arias C, Prins GS, Perrin M, Vale W, Sawchenko PE: Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol 2000, 428(2):191-212.
• [65]Ventura-Juncá R, Herrera L: Epigenetic alterations related to early-life stressful events. Acta Neuropsychiatrica 2012, 24:255-265.
• [66]Duman RS, Monteggia LM: A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006, 59(12):1116-1127.
• [67]Dalton VS, Kolshus E, McLoughlin DM: Epigenetics and depression: return of the repressed. J Affect Disord 2013, 155:1-12.
• [68]Hennings JM, Owashi T, Binder EB, Horstmann S, Menke A, Kloiber S, Dose T, Wollweber B, Spieler D, Messer T, Lutz R, Kunzel H, Bierner T, Pollmacher T, Pfister H, Nickel T, Sonntag A, Uhr M, Ising M, Holsboer F, Lucae S: Clinical characteristics and treatment outcome in a representative sample of depressed inpatients - findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res 2009, 43(3):215-229.